

Lipum AB - Report from the Extraordinary General Meeting

An Extraordinary General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (“Lipum” or the “Company”), today resolved to amend the Company’s articles of association and to approve the Board of Directors’ resolution on a rights issue of up to 27,944,055 shares. The EGM further resolved to approve the master services agreement which the Company entered into with NorthX Biologics AB on 29 February 2024.

At the EGM held on 2 April 2024, the general meeting resolved, in accordance with the proposed resolutions, as follows:

Resolution on a) amendment of the articles of association and b) approval of the Board of Directors’ resolution on a rights issue

The EGM resolved, in accordance with the Board of Directors’ proposal, to

- a. amend 4-5 §§ of the articles of association so that the share capital shall be not less than SEK 4,564,191.75 and not more than SEK 18,256,767.00 and that the number of shares shall be not less than 18,256,767 and not more than 73,027,068; and
- b. approve the Board of Directors’ resolution on 29 February 2024 on a rights issue of up to 27,944,055 shares at a subscription price of SEK 6.70 per share.

Resolution on approval of master services agreement with NorthX

The EGM further resolved, in accordance with the Board of Directors’ proposal, to approve the master services agreement entered into with NorthX Biologics AB on 29 February 2024.

The minutes of the EGM (in Swedish) will be available on Lipum’s website, www.lipum.se.

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

PRESS RELEASE

02 April 2024 13:25:00 CEST

**About Us**

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments

[Lipum AB - Report from the Extraordinary General Meeting](#)